Skip to main content
PMC home page
Immunology logoLink to Immunology
. 1987 Feb;60(2):255–260.

Clearance kinetics and organ uptake of complement-solubilized immune complexes in mice.

M T Aguado, M Mannik
PMCID: PMC1453216  PMID: 3817872

Abstract

C3-bearing immune complexes were prepared by in vitro solubilization of BSA-anti-BSA complexes at equivalence. Sucrose density gradient analyses showed a size-heterogeneous population of solubilized complexes with a range of 7S to greater than 29S and a peak at around 19S. The presence of C3bi was demonstrated by precipitation with antibodies to C3c and to C3d and by binding to conglutinin. Immune complexes solubilized in two and three times antigen excess were selected as controls due to their size similarities with complement-solubilized complexes. Blood clearance curves were very similar for C3-bearing complexes and controls. At 1 hr, the percentage of injected material remaining in the circulation for complement-solubilized and two and three times antigen excess complexes were 29.5 +/- 1.3, 30.9 +/- 1.7 and 26.1 +/- 2.7, respectively. Uptake by liver accounted for the majority of complement- and antigen-solubilized immune complexes removed from circulation. Although the uptake by the spleen was no more than one-tenth of the liver uptake, more complement-solubilized complexes than antigen-solubilized complexes were removed by this organ. The present data indicate that soluble immune complexes bearing C3 components and soluble immune complexes without C3 components, but of comparable size, are cleared from the circulation of mice at comparable rates. The mechanisms of clearance of these two populations of complexes, however, may differ.

Full text

PDF
255

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agodoa L. Y., Gauthier V. J., Mannik M. Precipitating antigen-antibody systems are required for the formation of subepithelial electron-dense immune deposits in rat glomeruli. J Exp Med. 1983 Oct 1;158(4):1259–1271. doi: 10.1084/jem.158.4.1259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aguado M. T., Perrin L. H., Miescher P. A., Lambert P. H. Decreased capacity to solubilize immune complexes in sera from patients with systemic lupus erythematosus. Arthritis Rheum. 1981 Oct;24(10):1225–1229. doi: 10.1002/art.1780241001. [DOI] [PubMed] [Google Scholar]
  3. Baatrup G., Petersen I., Jensenius J. C., Svehag S. E. Reduced complement-mediated immune complex solubilizing capacity and the presence of incompletely solubilized immune complexes in SLE sera. Clin Exp Immunol. 1983 Nov;54(2):439–447. [PMC free article] [PubMed] [Google Scholar]
  4. Baatrup G., Petersen I., Kappelgaard E., Jepsen H. H., Svehag S. E. Complement-mediated solubilization of immune complexes. Solubilization inhibition and complement factor levels in SLE patients. Clin Exp Immunol. 1984 Feb;55(2):313–318. [PMC free article] [PubMed] [Google Scholar]
  5. Beller D. I., Springer T. A., Schreiber R. D. Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor. J Exp Med. 1982 Oct 1;156(4):1000–1009. doi: 10.1084/jem.156.4.1000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bockow B., Mannik M. Clearance and tissue uptake of immune complexes in complement-depleted and control mice. Immunology. 1981 Apr;42(4):497–504. [PMC free article] [PubMed] [Google Scholar]
  7. Casali P., Lambert P. H. Purification of soluble immune complexes from serum using polymethylmetacrylate beads coated with conglutinin or C1q. Application to the analysis of the components of in vitro formed immune complexes and of immune complexes occurring in vivo during leishmaniasis. Clin Exp Immunol. 1979 Aug;37(2):295–309. [PMC free article] [PubMed] [Google Scholar]
  8. Fujita T., Takata Y., Tamura N. Solubilization of immune precipitates by six isolated alternative pathway proteins. J Exp Med. 1981 Dec 1;154(6):1743–1751. doi: 10.1084/jem.154.6.1743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gadd K. J., Reid K. B. The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum. Biochem J. 1981 May 1;195(2):471–480. doi: 10.1042/bj1950471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Maire M. A., Barnet M., Lambert P. H. Purification of bovine conglutinin using pepsin digestion. Mol Immunol. 1981 Feb;18(2):85–89. doi: 10.1016/0161-5890(81)90073-0. [DOI] [PubMed] [Google Scholar]
  11. Malasit P., Bartolotti S. R., Humphrey J. H. Molecular composition of complement-solubilized complexes and their fate in vivo. Immunology. 1983 Apr;48(4):779–789. [PMC free article] [PubMed] [Google Scholar]
  12. Mannik M., Agodoa L. Y., David K. A. Rearrangement of immune complexes in glomeruli leads to persistence and development of electron-dense deposits. J Exp Med. 1983 May 1;157(5):1516–1528. doi: 10.1084/jem.157.5.1516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mannik M., Arend M. P., Hall A. P., Gilliland B. C. Studies on antigen-antibody complexes. I. Elimination of soluble complexes from rabbit circulation. J Exp Med. 1971 Apr 1;133(4):713–739. doi: 10.1084/jem.133.4.713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Miller G. W., Nussenzweig V. A new complement function: solubilization of antigen-antibody aggregates. Proc Natl Acad Sci U S A. 1975 Feb;72(2):418–422. doi: 10.1073/pnas.72.2.418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Naama J. K., Hamilton A. O., Yeung-Laiwah A. C., Whaley K. Prevention of immune precipitation by purified classical pathway complement components. Clin Exp Immunol. 1984 Nov;58(2):486–492. [PMC free article] [PubMed] [Google Scholar]
  16. Naama J. K., Holme E., Hamilton E., Whaley K. Prevention of immune precipitation by purified components of the alternative pathway. Clin Exp Immunol. 1985 Apr;60(1):169–177. [PMC free article] [PubMed] [Google Scholar]
  17. Scharfstein J., Correa E. B., Gallo G. R., Nussenzweig V. Human C4-binding protein. Association with immune complexes in vitro and in vivo. J Clin Invest. 1979 Mar;63(3):437–442. doi: 10.1172/JCI109320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Schifferli J. A., Bartolotti S. R., Peters D. K. Inhibition of immune precipitation by complement. Clin Exp Immunol. 1980 Nov;42(2):387–394. [PMC free article] [PubMed] [Google Scholar]
  19. Schifferli J. A., Morris S. M., Dash A., Peters D. K. Complement-mediated solubilization in patients with systemic lupus erythematosus, nephritis or vasculitis. Clin Exp Immunol. 1981 Dec;46(3):557–564. [PMC free article] [PubMed] [Google Scholar]
  20. Schifferli J. A., Peters D. K. Immune adherence and staphylococcus protein A binding of soluble immune complexes produced by complement activation. Clin Exp Immunol. 1983 Dec;54(3):827–833. [PMC free article] [PubMed] [Google Scholar]
  21. Schifferli J. A., Woo P., Peters D. K. Complement-mediated inhibition of immune precipitation. I. Role of the classical and alternative pathways. Clin Exp Immunol. 1982 Mar;47(3):555–562. [PMC free article] [PubMed] [Google Scholar]
  22. Takahashi N., Fujita T., Takata Y., Tamura N. Interaction of complement solubilized complexes with mouse peritoneal macrophages and their clearance and tissue uptake. Clin Exp Immunol. 1985 Jul;61(1):176–182. [PMC free article] [PubMed] [Google Scholar]
  23. Takata Y., Tamura N., Fujita T. Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates. J Immunol. 1984 May;132(5):2531–2537. [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES